C.R. Bard, Inc.

  • A Legendary Growth Investor Keeps Buying These Stocks

    By Ted Cooper - August 12, 2013 | Tickers: BCR, KO, SYY

    Donald Yacktman, manager of his eponymous $21 billion mutual fund company, has compounded his clients' money at 10.1% per annum over the last two decades -- the S&P 500 returned just over 8% in the same period. So when Yacktman buys a stock, investors should take note.

    Yacktman combines the best features of growth and value investing by purchasing growing companies at low prices. He looks for good businesses more »

  • This Acquisition Will Improve Abbott's Business

    By Kanak Kanti - July 29, 2013 | Tickers: ABT, BCR, COV

    Abbott Laboratories' (NYSE: ABT) bid to acquire IDEV Technologies by end-2013 will strengthen the former’s medical devices (Abbott Vascular) business especially in stent offerings for pulmonary arterial diseases (PAD). Abbott Vascular represents roughly 14% of Abbott's total sales, and that mostly comprises various types of drug eluting stents (DES). However, PAD is another very important type of stent that Abbott does not cover at present. IDEV's expertise more »

  • Finding Strength in Medical Supplies

    By Nathaniel Matherson - June 26, 2013 | Tickers: BCR, ROCM, TFX

    As of late I have been looking to take advantage of a few major themes set to accelerate over the upcoming decades. In my recent articles I have taken a look a companies poised to benefit from the drastic rise in healthcare demand. The surge in demand will be fueled by our aging population in combination with greater accessibility for the masses. I continued this search last weekend and stumbled more »

  • This Medical Company Is Not Cheap

    By Anh HOANG - May 2, 2013 | Tickers: BDX, BCR, COV

    Recently, Covidien (NYSE: COV) witnessed a significant decline of nearly 7% after it announced sluggish second-quarter earnings. Even after the drop, Covidien’s share price has gained more than 7.3% since the beginning of the year. The company is currently in the portfolios of several famous investors including Ray Dalio, Steven Cohen, and Paul Tudor Jones. Should we consider a recent drop in its share price as an investment more »

  • Buy This Healthcare Outperformer

    By Piyush Arora - April 19, 2013 | Tickers: BAX, BDX, BCR

    The healthcare industry is known to have a stable topline and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26%, respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think the healthcare industry is still ripe for value more »

  • Buy This Healthcare Outperformer

    By Piyush Arora - April 6, 2013 | Tickers: BAX, BDX, BCR

    The healthcare industry is known to have a stable topline and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26%, respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think the healthcare industry is still ripe for value more »

  • Buy This Healthcare Outperformer

    By Piyush Arora - April 6, 2013 | Tickers: BAX, BDX, BCR

    The healthcare industry is known to have a stable topline and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26%, respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think the healthcare industry is still ripe for value more »

  • An Outperformer in Healthcare

    By Piyush Arora - April 3, 2013 | Tickers: BAX, BDX, BCR

    Healthcare industry is known to have a stable topline and steady rewards and usually attracts income growth investors. But over the last year, shares of Baxter International (NYSE: BAX) and Becton, Dickinson & Co. (NYSE: BDX) have risen by nearly 25% and 26% respectively. These companies have not only outperformed their peers, but also carry a solid yield. But despite the recent rally, I think Healthcare industry is still ripe for more »

  • A Value Play in Healthcare

    By Piyush Arora - February 23, 2013 | Tickers: BAX, BDX, BCR

    According to various sources, around 78.3 million babies were born in the US, between 1946 and 1964 i.e. post World War 2. People of this generation are often referred as baby boomers, the era is remembered as the baby boom. Today, those babies have grown up and are aged between 49 and 67 years. It’s a well-known fact that the elderly have greater health concerns, and those more »

  • Can This Diversified Healthcare Company Keep Investor’s Portfolios Healthy?

    By Ryan Guenette - January 10, 2013 | Tickers: BAX, BCR, COV, HSP, SYK

    A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a tremendous way to gain a detailed and thorough perspective on a company and its future. As the 2012 year draws to a close, I would like to pinpoint on a diversified healthcare company, operating in the medical devices, pharmaceuticals, and biotechnology industries, Baxter International Incorporated (NYSE: BAX).

     

    Strengths:

  • 5 Stocks Loved By This Three Billion Dollar Man

    By Meena Krishnamsetty - November 30, 2012 | Tickers: ANF, AGN, BCR, CAH, TIF

    Paul Tudor Jones founded Tudor Investment in 1980 and has a net worth over $3 billion. His fund focuses on short term trading and charges a fee that is above industry standards, charging a 4% management fee and 23% performance fee, compared to the standard 2-and-20 structure. Tudor recently filed its 13F with the SEC, which reveals public equity holdings of the firm as of the end of the third more »

  • Long-Term Investment Ideas from Value Investor Jeffrey Ubben

    By Meena Krishnamsetty - September 13, 2012 | Tickers: ADBE, BCR, MSFT, MSI, VRX

    Jeffrey Ubben founded ValueAct Capital and, since 2000, has served as its CEO and CIO. Prior to founding and managing his own fund, Ubben was a managing partner at Richard Blum’s Blum Capital Partners for five years. ValueAct tends to focus its efforts on effecting change at a small number of companies, so its portfolio remains relatively focused and stable. The fund usually makes only three to four new more »

  • Covidien: A Conviction Buy

    By Ashish Sharma - August 24, 2012 | Tickers: BSX, BCR, COV, STJ

    Covidien (NYSE: COV) is a worldwide leader in Medical Devices & Diagnostics products. The company operates through three segments: Medical Devices, Pharmaceutical/Imaging Products, and Medical Supplies. Late last month, Covidien reported fiscal 3Q results with sales of $3 billion (up 3% YoY) and EPS of $1.07 vs. the consensus estimates of $1.06. Adjusted gross margin rose 90 basis points YoY to 58.0%, while R&D spending increased more »

  • Medtronic – Market Volatility Medicine for your Portfolio

    By Paul Franke - February 22, 2012 | Tickers: ABT, BDX, BCR, JNJ, MDT, STJ | Editor's Choice

    Medtronic (NYSE: MDT) hits the mark for Quantemonics Investing (QI) as a terrific low beta, blue-chip investment idea that is both undervalued and defensive.  Using the Quanteminics C.R.E.D.S. formula, MDT has been an exceptional value for new investors, trading under $40 per share in 2011 and early 2012.

  • Price The Market Part 35

    By Glen Bradford - January 9, 2012 | Tickers: AET, BAX, BDX, BIIB, BCR

    Hello again, to all my friends and foes. It's the foes that keep you on your toes, don't you know? If you didn't, now you do. Let's do this. LEEROOOOOY JEEEEENKINS!

    241. Biogen IDEC Inc. (NASDAQ: BIIB) is fairly priced at present at first glance. George Soros is no dummy and he bought below $100. Notably there was a huge sale recently by the CFO at more »